Notably, SFN has demonstrated a capacity to counteract amyloid β (Aβ) aggregation in Alzheimer’s disease, with this effect being correlated with the activation of Nrf2 [90]. Here, NFE2L2 is linked to early-onset autosomal dominant Alzheimer disease.